URCC-21038

Please Note:

The purpose of this study is to understand the treatment experiences and outcomes of both Black and White patients on Immune Checkpoint Inhibitors. We want to make sure that all patients regardless of race can benefit from this new type of cancer treatment. There will be about 1,800 patients taking part in this study across the nation through the NCORP network. Our ultimate goal is to make sure all patients can benefit from this treatment, with minimum side effects and maximum benefits.

Available Sites

• Missouri Baptist Medical Center

Contact Person(s)

• Monica Russo 314-996-5868
• MBMC, Henry Robinson, 314-996-5865

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.